{"id":737,"date":"2020-06-29T13:07:24","date_gmt":"2020-06-29T13:07:24","guid":{"rendered":"https:\/\/blogs.bmj.com\/jnnp\/?p=737"},"modified":"2020-06-29T13:07:24","modified_gmt":"2020-06-29T13:07:24","slug":"new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/","title":{"rendered":"New drugs new adverse effects: Neurology and immune checkpoint inhibitors"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p>Checkpoint inhibitor drugs are a relatively new immunotherapy for cancer, showing outstanding clinical efficacy in various tumors, including lung cancer and melanoma. By improving the immune response to disease, these drugs also trigger immune-mediated side effects, which can compromise the nervous system. Among all the neurological complications, the peripheral nervous system (PNS) is commonly affected by neuropathy, myasthenia gravis, and myositis. However, central nervous system (CNS) complications by immune checkpoint inhibitors (ICIs) are less characterized, and knowledge regarding clinical, imaging, and treatment responses are scarce.<\/p>\n<p>In the July issue of JNNP, Vogrig and colleagues describe the largest cohort of patients with CNS complications secondary to ICIs (Figure 1). Retrospectively, patients were selected from the French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (Lyon, France) and clinical and ancillary data were extracted. A total of 19 patients were identified, of whom 8 patients presented with limbic encephalitis, 4 with meningoencephalitis and 4 with cerebellitis. Two patients developed isolated confusion and one parkinsonism. Regarding autoantibody studies the most commonly detected were onconeural antibodies, followed by astrocytic and neuronal surface antibodies. As part of the treatment, in all patients ICIs were withdrawn and corticosteroids were used. Another treatment used was IVIG, rituximab, plasmapheresis and infliximab. The series mortality was 32% (6 cases). When the authors compared patients with CNS dysfunction versus PNS dysfunction triggered by ICIs, the former had significantly more frequent non-small-cell lung cancer (NSCLC; p&lt;0.01) and positive autoantibodies (p&lt;0.01) than patients with PNS dysfunction. There was a trend towards a poorer outcome in the CNS group.<\/p>\n<figure id=\"attachment_738\" aria-describedby=\"caption-attachment-738\" style=\"width: 573px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\" wp-image-738\" src=\"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg\" alt=\"Checkpoint inhibitor drugs are a relatively new immunotherapy for cancer, showing outstanding clinical efficacy in various tumors, including lung cancer and melanoma. By improving the immune response to disease, these drugs also trigger immune-mediated side effects, which can compromise the nervous system. Among all the neurological complications, the peripheral nervous system (PNS) is commonly affected by neuropathy, myasthenia gravis, and myositis. However, central nervous system (CNS) complications by immune checkpoint inhibitors (ICIs) are less characterized, and knowledge regarding clinical, imaging, and treatment responses are scarce. In the July issue of JNNP, Vogrig and colleagues describe the largest cohort of patients with CNS complications secondary to ICIs. Retrospectively, patients were selected from the French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis (Lyon, France) and clinical and ancillary data were extracted. A total of 19 patients were identified, of whom 8 patients presented with limbic encephalitis, 4 with meningoencephalitis and 4 with cerebellitis. Two patients developed isolated confusion and one parkinsonism. Regarding autoantibody studies the most commonly detected were onconeural antibodies, followed by astrocytic and neuronal surface antibodies. As part of the treatment, in all patients ICIs were withdrawn and corticosteroids were used. Another treatment used was IVIG, rituximab, plasmapheresis and infliximab. The series mortality was 32% (6 cases). When the authors compared patients with CNS dysfunction versus PNS dysfunction triggered by ICIs, the former had significantly more frequent non-small-cell lung cancer (NSCLC; p&lt;0.01) and positive autoantibodies (p&lt;0.01) than patients with PNS dysfunction. There was a trend towards a poorer outcome in the CNS group. ICIs have become standard treatments for many cancers; therefore, neurologists should be aware of the immune-related adverse events associated with this new drug group. In this JNNP article three main clinical phenotypes (limbic encephalitis, meningoencephalitis and cerebellitis) were fully characterized to understand the clinical picture and outcome of CNS dysfunction secondary to ICIs. Of interest, this group of patients frequently have NSCLC, positive autoantibodies and worse outcome. Given the lack of biomarkers for diagnosis, it is crucial not to forget to exclude a wide range of disorders including infectious, metabolic, endocrine or metastatic diseases in this group of patients. Further studies are needed to understand the immunopathogenesis, define specific treatment approaches, and identify patients with cancer who are at risk of developing CNS dysfunction triggered by ICIs. Read more at https:\/\/jnnp.bmj.com\/content\/91\/7\/772\" width=\"573\" height=\"279\" srcset=\"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg 1858w, https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1-300x146.jpg 300w, https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1-1024x498.jpg 1024w, https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1-768x374.jpg 768w, https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1-1536x747.jpg 1536w, https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1-640x311.jpg 640w\" sizes=\"auto, (max-width: 573px) 100vw, 573px\" \/><\/a><figcaption id=\"caption-attachment-738\" class=\"wp-caption-text\"><strong>Figure 1. Immune checkpoint inhibitors and CNS disorders<\/strong><\/figcaption><\/figure>\n<p>&nbsp;<\/p>\n<p>ICIs have become standard treatments for many cancers; therefore, neurologists should be aware of the immune-related adverse events associated with this new drug group. In this JNNP article three main clinical phenotypes (limbic encephalitis, meningoencephalitis and cerebellitis) were fully characterized to understand the clinical picture and outcome of CNS dysfunction secondary to ICIs. Of interest, this group of patients frequently have NSCLC, positive autoantibodies and worse outcome. Given the lack of biomarkers for diagnosis, it is crucial not to forget to exclude a wide range of disorders including infectious, metabolic, endocrine or metastatic diseases in this group of patients. Further studies are needed to understand the immunopathogenesis, define specific treatment approaches, and identify patients with cancer who are at risk of developing CNS dysfunction triggered by ICIs.<\/p>\n<p>Read more at <span style=\"color: #0000ff\"><strong>https:\/\/jnnp.bmj.com\/content\/91\/7\/772<\/strong><\/span><\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Checkpoint inhibitor drugs are a relatively new immunotherapy for cancer, showing outstanding clinical efficacy in various tumors, including lung cancer and melanoma. By improving the immune response to disease, these drugs also trigger immune-mediated side effects, which can compromise the nervous system. Among all the neurological complications, the peripheral nervous system (PNS) is commonly [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":297,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-737","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New drugs new adverse effects: Neurology and immune checkpoint inhibitors - JNNP blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New drugs new adverse effects: Neurology and immune checkpoint inhibitors - JNNP blog\" \/>\n<meta property=\"og:description\" content=\"&nbsp; Checkpoint inhibitor drugs are a relatively new immunotherapy for cancer, showing outstanding clinical efficacy in various tumors, including lung cancer and melanoma. By improving the immune response to disease, these drugs also trigger immune-mediated side effects, which can compromise the nervous system. Among all the neurological complications, the peripheral nervous system (PNS) is commonly [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/\" \/>\n<meta property=\"og:site_name\" content=\"JNNP blog\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-29T13:07:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg\" \/>\n<meta name=\"author\" content=\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/\"},\"author\":{\"name\":\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/person\\\/ae8ff1db7900136065ad542015291a0b\"},\"headline\":\"New drugs new adverse effects: Neurology and immune checkpoint inhibitors\",\"datePublished\":\"2020-06-29T13:07:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/\"},\"wordCount\":417,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2020\\\/06\\\/Figure-1.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/\",\"name\":\"New drugs new adverse effects: Neurology and immune checkpoint inhibitors - JNNP blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2020\\\/06\\\/Figure-1.jpg\",\"datePublished\":\"2020-06-29T13:07:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2020\\\/06\\\/Figure-1.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2020\\\/06\\\/Figure-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/2020\\\/06\\\/29\\\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New drugs new adverse effects: Neurology and immune checkpoint inhibitors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\",\"name\":\"JNNP blog\",\"description\":\"The official JNNP blog. A place to discuss wider neurology beyond the journal&#039;s monthly edition.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#organization\",\"name\":\"JNNP blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2017\\\/11\\\/blog-logo-jnnp1.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/files\\\/2017\\\/11\\\/blog-logo-jnnp1.png\",\"width\":427,\"height\":34,\"caption\":\"JNNP blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/#\\\/schema\\\/person\\\/ae8ff1db7900136065ad542015291a0b\",\"name\":\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g\",\"caption\":\"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.\"},\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jnnp\\\/author\\\/jmatamalacapponi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New drugs new adverse effects: Neurology and immune checkpoint inhibitors - JNNP blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/","og_locale":"en_US","og_type":"article","og_title":"New drugs new adverse effects: Neurology and immune checkpoint inhibitors - JNNP blog","og_description":"&nbsp; Checkpoint inhibitor drugs are a relatively new immunotherapy for cancer, showing outstanding clinical efficacy in various tumors, including lung cancer and melanoma. By improving the immune response to disease, these drugs also trigger immune-mediated side effects, which can compromise the nervous system. Among all the neurological complications, the peripheral nervous system (PNS) is commonly [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/","og_site_name":"JNNP blog","article_published_time":"2020-06-29T13:07:24+00:00","og_image":[{"url":"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg","type":"","width":"","height":""}],"author":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/"},"author":{"name":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/person\/ae8ff1db7900136065ad542015291a0b"},"headline":"New drugs new adverse effects: Neurology and immune checkpoint inhibitors","datePublished":"2020-06-29T13:07:24+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/"},"wordCount":417,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/","url":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/","name":"New drugs new adverse effects: Neurology and immune checkpoint inhibitors - JNNP blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg","datePublished":"2020-06-29T13:07:24+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2020\/06\/Figure-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jnnp\/2020\/06\/29\/new-drugs-new-adverse-effects-neurology-and-immune-checkpoint-inhibitors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jnnp\/"},{"@type":"ListItem","position":2,"name":"New drugs new adverse effects: Neurology and immune checkpoint inhibitors"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jnnp\/#website","url":"https:\/\/blogs.bmj.com\/jnnp\/","name":"JNNP blog","description":"The official JNNP blog. A place to discuss wider neurology beyond the journal&#039;s monthly edition.","publisher":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jnnp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jnnp\/#organization","name":"JNNP blog","url":"https:\/\/blogs.bmj.com\/jnnp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jnnp\/files\/2017\/11\/blog-logo-jnnp1.png","contentUrl":"https:\/\/blogs.bmj.com\/jnnp\/files\/2017\/11\/blog-logo-jnnp1.png","width":427,"height":34,"caption":"JNNP blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jnnp\/#\/schema\/person\/ae8ff1db7900136065ad542015291a0b","name":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor.","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e1b1c0ce10538e3596d7c2c2ee986ea6a4e955673bbe9904c181a4e55a65cc9e?s=96&d=mm&r=g","caption":"Dr Jos\u00e9 Manuel Matamala, JNNP web editor."},"url":"https:\/\/blogs.bmj.com\/jnnp\/author\/jmatamalacapponi\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/users\/297"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/comments?post=737"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/posts\/737\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/media?parent=737"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/categories?post=737"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jnnp\/wp-json\/wp\/v2\/tags?post=737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}